91
Participants
Start Date
May 31, 2004
Primary Completion Date
August 31, 2007
Study Completion Date
August 31, 2007
Live vaccinia virus vaccine
Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.
MVA Smallpox Vaccine
Imvamune/MVA-BN 1x10\^8 will be administered intramuscularly to Group F on day 0 and day 28.
MVA Smallpox Vaccine
Imvamune/MVA-BN Groups A, B C and E will be administered subcutaneously: 2x10\^7, 5x10\^7, 1x10\^8, 1x10\^8, respectively, on days 0 and day 28.
Placebo
Group E will receive sterile saline placebo for injection via scarification on day 112.
Placebo
Group D will receive sterile saline placebo for injection subcutaneously on day 0 and day 28.
Saint Louis University, St Louis
National Institute of Allergy and Infectious Diseases (NIAID)
NIH